Pharmaceuticals MDPI ads

🌟 Meet Our Plenary Speaker: Prof. Dr. Balázs Sarkadi 🌟 We are delighted to announce Prof. Dr. Balázs Sarkadi, HUN-REN Research Centre for Natural Sciences HUN-REN Hungarian Research Network and Semmelweis University Semmelweis University, Budapest, Hungary, and Full Member of the Hungarian Academy of Sciences Hungarian Academy of Sciences, as a Plenary Speaker at the 2nd International Conference on Pharmaceuticals and New Trends in Drug Discovery (ICOPharm-2). 🔬 Prof. Dr. Sarkadi’s research focuses on membrane proteins and transporters involved in multidrug resistance, cancer, stem cell function, and pharmacology. His recent work explores stem-cell-derived tissues and organoids, with exciting applications in drug discovery and development. We look forward to hearing his insights into emerging advances in drug discovery, pharmacology, and organoid-based research at ICOPharm-2! 📍 Lisbon, Portugal 📅 11–14 May 2027 ⏰ Abstract Submission Deadline: 15 January 2027 🎟️ Early Bird Registration Deadline: 26 February 2027 🔗 Register: https://lnkd.in/grz4QsGh Join us in Lisbon and be part of the conversation shaping the future of pharmaceutical research and drug discovery! 🌍🧬 #ICOPharm2027 #MDPIConference #DrugDiscovery #DrugDevelopment #Pharmacology #Organoids #PharmaceuticalSciences #AcademicConference

🌟 Meet Our Plenary Speaker: Prof. Dr. José Manuel García Fernández 🌟 We are delighted to welcome Prof. Dr. José Manuel García Fernández from the Institute for Chemical Research (IIQ), CSIC–University of Seville CSIC, Spain, as a Plenary Speaker at the 2nd International Conference on Pharmaceuticals and New Trends in Drug Discovery (ICOPharm-2), taking place 11–14 May 2027 in Lisbon, Portugal ❤️ 🔬 Prof. García Fernández’s research focuses on carbohydrate chemistry, with particular interests in glycodrugs, drug and gene delivery, and carbohydrate-based pharmaceutical technologies. 🥰 We look forward to hearing his insights into the latest advances in glycodrug development and targeted drug delivery at ICOPharm-2! 📅 Abstract Submission Deadline: 15 January 2027 🎟️ Early Bird Registration Deadline: 26 February 2027 🔗 Register: https://lnkd.in/grz4QsGh #ICOPharm2027 #MDPIConference #DrugDiscovery #DrugDevelopment #DrugDelivery #Glycodrugs #PharmaceuticalResearch #CarbohydrateChemistry #AcademicConference

🔥 Hot Paper of 2026 | #BPC157 Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats by Madzarac et al. Hightlight 🍬 The study investigates the effects of stable gastric pentadecapeptide BPC 157 therapy on tracheocutaneous fistulas in rats, focusing on the relationship between fistula healing and the nitric oxide (NO) system over a 7-day period. 🍬 The research demonstrates that tracheocutaneous fistulas are associated with significant clinical signs of respiratory distress and failed healing, characterized by various symptoms such as open-mouth breathing, cyanosis, and weight loss. 🍬 BPC 157 therapy, administered through different routes, resulted in rapid recovery, including the healing of skin and tracheal defects, closure of the fistula, and improvement in clinical signs, effectively counteracting the negative effects of NO system blockade and over-activity. 🍬 The findings suggest that BPC 157 enhances the effects of L-arginine, mitigates the adverse effects of L-NAME, and restores full healing by acting through the NO system, ultimately reversing the course of tracheocutaneous fistulas in the studied rats. Enjoy reading: https://lnkd.in/g3Cnyd6t

🔥 Hot Paper of 2026 | #Antimalarial Targeting Infected Host Cell Heme Metabolism to Kill Malaria Parasites by Siddiqui et al. Hightlight 🪁 The study focuses on exploiting host red blood cell (RBC) heme metabolism as a therapeutic vulnerability to enhance the efficacy of artemisinin-based therapies against malaria, particularly in the context of increasing drug resistance. 🪁 A "bait-and-kill" strategy was developed, utilizing the heme precursor 5-aminolevulinic acid (ALA) to sensitize malaria-infected RBCs (iRBCs) to the killing effects of dihydroartemisinin (DHA), resulting in synergistic parasite elimination. 🪁 The research found that mature RBCs can accumulate porphyrin intermediates due to a truncated heme biosynthesis pathway, while iRBCs have increased membrane permeability that allows selective uptake of ALA, leading to porphyrin accumulation without cytotoxicity. 🪁 The combination of ALA and DHA effectively cleared artemisinin-resistant Plasmodium falciparum isolates, demonstrating the potential of this host-directed approach to bypass drug resistance and improve malaria treatment outcomes. Enjoy reading: https://lnkd.in/gtyN3F_H

🔥 Hot Paper of 2026 | #Radiopharmaceuticals CopperNostics—Here We Are Now, Entertain Us! by Brühlmann et al. Hightlight 🥬 Definition and Importance: The paper discusses "CopperNostics," which refers to the use of copper radioisotopes in diagnosis and endoradiotherapy, highlighting its significance in modern precision medicine. 🥬 FDA Approval: The review mentions the FDA approval of [64Cu]Cu-DOTA-TATE (Detectnet), indicating a milestone in the application of copper radioisotopes in clinical settings. 🥬 Focus on Copper Radioisotopes: The authors emphasize the production, radiochemical purification, quality control, availability, logistics, and regulatory challenges associated with key copper radioisotopes, specifically 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu. 🥬 Clinical Applications: The review presents the use of radiopharmaceuticals derived from these copper radioisotopes in registered clinical trials, addressing their roles as molecular imaging agents, companion diagnostics, and therapeutic agents to meet unmet medical needs. Enjoy reading: https://lnkd.in/gHbfDv-6

🔥 Hot Paper of 2026 | #Imperatorin Imperatorin: A Furanocoumarin with Potential in Combating Cancer Development and Progression—A Comprehensive Review by Rodrigues et al. Hightlight 🍇 Antitumor Mechanisms: Imperatorin exhibits multi-targeted antitumor effects, including inducing apoptosis, inhibiting proliferation, suppressing angiogenesis, modulating oxidative stress, and disrupting oncogenic signaling pathways such as PI3K/Akt, MAPK, mTOR, and NF-κB. 🍇 Impact on Tumor Microenvironment: The compound influences the tumor microenvironment by reducing pro-inflammatory mediators, impairing stromal-tumor interactions, and enhancing immune-cell-mediated cytotoxicity. 🍇 Pharmacokinetic and Safety Challenges: There are significant limitations to the clinical translation of imperatorin, including low oral bioavailability, extensive plasma protein binding, interactions with cytochrome P450, and insufficient toxicological data. 🍇 Future Research Directions: The review emphasizes the need for improved delivery strategies, further investigation into regulatory pathways, and more robust in vivo studies, as well as a deeper understanding of imperatorin's effects on autophagy, ferroptosis, and the immune microenvironment. Enjoy reading: https://lnkd.in/gwD6PtF5